Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
Physicians’ ethical obligations to disclose conflicts of interest to patients and to obtain their informed consent for treatment are particularly critical when proposed treatments are experimental.